Trial Profile

A Randomised Double-blind Placebo-controlled Clinical Trial Investigating the Effect and Safety of Oral Semaglutide in Subjects With Early Alzheimer´s Disease (EVOKE)

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 12 Apr 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Semaglutide (Primary)
Indications Alzheimer's disease
Focus Registrational; Therapeutic Use
Acronyms EVOKE
Sponsors Novo Nordisk

Most Recent Events

29 May 2024 Abstracts reporting the preliminary baseline characteristics from evoke (NCT04777396) and evoke+ (NCT04777409) trial , to be presented at the 2024 AAN Annual Meeting, being held April 13-18 in Denver.
01 Jul 2023 Status changed from recruiting to active, no longer recruiting.
07 Dec 2022 Planned primary completion date changed from 9 Aug 2024 to 19 Sep 2025.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com